<DOC>
	<DOC>NCT02053883</DOC>
	<brief_summary>This is a multicenter, randomized, double-blind, placebo-controlled Phase IIb/III study designed to evaluate the efficacy and safety of Cethrin as a treatment for acute cervical spinal cord injury. During the trial, high and low doses of Cethrin will be compared with placebo.</brief_summary>
	<brief_title>Cethrin in Acute Cervical Spinal Cord Injury</brief_title>
	<detailed_description />
	<mesh_term>Wounds and Injuries</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Fibrin Tissue Adhesive</mesh_term>
	<criteria>Males or females, ages 1862, inclusive Acute cervical spinal cord injury at a neurological level of C4C6 AIS Grade A or B Scheduled to undergo decompression/stabilization surgery within five days of injury Written or verbal consent from patient or legally authorized representative that patient is able and willing to comply with the study protocol, including followup visits Participation in any other clinical trial for acute SCI, including previous Cethrin trial Inability to receive study medication within five days of injury Acute SCI from gunshot or penetrating/stab wound; peripheral nerve injury; brachial plexus injury; complete spinal cord transection; or multifocal SCI Significant hemorrhage on MRI/CT scan Females who are breastfeeding or have a positive serum pregnancy test Body mass index (BMI) of â‰¥ 35 kg/m2 at screening History of an adverse reaction to a fibrin sealant or its human or bovine components Use of intravenous heparin in previous 48 hours, aspirincontaining products in previous 24 hours, thrombolytics in previous 12 hours Hemophilia or other bleeding abnormality (platelet level lower than 100 X 109/L, activated partial thromboplastin time or international normalized ratio higher than the upper limit of normal, or baseline hematocrit lower than 0.25) Unconsciousness or other impairment that precludes reliable ASIA examination Known immunodeficiency, including human immunodeficiency virus, or use of immunosuppressive or cancer chemotherapeutic drugs Clinically significant preexisting neurological, cardiac, respiratory, hepatic, or renal disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>62 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>SCI</keyword>
	<keyword>spinal cord injury</keyword>
	<keyword>biologic drug</keyword>
	<keyword>rho</keyword>
	<keyword>paralysis</keyword>
	<keyword>paraplegia</keyword>
	<keyword>tetraplegia</keyword>
	<keyword>quadriplegia</keyword>
	<keyword>trauma</keyword>
	<keyword>central nervous system</keyword>
	<keyword>fibrin sealant</keyword>
	<keyword>neurosurgery</keyword>
	<keyword>cervical</keyword>
	<keyword>regeneration</keyword>
	<keyword>neurotrauma</keyword>
</DOC>